Androgen-deprivation therapy, which is a common treatment for prostate cancer, has been tentatively linked with an increased risk of cardiovascular disease. A new study solidifies these concerns.

Prostate cancer needs testosterone to grow and thrive, so androgen-deprivation therapy (ADT) is designed to reduce the amount of testosterone in the body to close to zero, thereby helping to slow cancer's growth.

Although the findings are controversial, some studies have shown that ADT combined with radiation therapy is more successful at treating prostate cancer than just radiation alone.

Currently, ADT is recommended for advanced prostate cancer. But it is increasingly being used to treat localized prostate cancer, despite minimal evidence for its efficacy.

At the same time, the number of localized prostate cancer cases has increased dramatically over recent years, due in part to the more widespread use of prostate-specific antigen (PSA) testing.

Side effects of ADT — including erectile dysfunction, diabetes, bone loss, and swollen breast tissue, or gynecomastia — can be fairly substantial. Added to this, there is growing evidence to suggest that low testosterone levels might increase the risk of cardiovascular disease (CVD).